Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

[Analysis of an iodide radioimmunoassay for 11-deoxicortisol measurement].

Madeira JL, Bussmann LZ, Lima-Valassi HP, Mendonça BB.

Arq Bras Endocrinol Metabol. 2014 Apr;58(3):232-6. Portuguese.

2.

Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry.

Janzen N, Peter M, Sander S, Steuerwald U, Terhardt M, Holtkamp U, Sander J.

J Clin Endocrinol Metab. 2007 Jul;92(7):2581-9. Epub 2007 Apr 24.

PMID:
17456574
3.

Simultaneous quantification of 17α-OH progesterone, 11-deoxycortisol, Δ4-androstenedione, cortisol and cortisone in newborn blood spots using liquid chromatography-tandem mass spectrometry.

Magnisali P, Chalioti MB, Livadara T, Mataragas M, Paliatsiou S, Malamitsi-Puchner A, Moutsatsou P.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Jun 1;879(19):1565-72. doi: 10.1016/j.jchromb.2011.03.048. Epub 2011 Apr 4.

PMID:
21514253
4.

Performance enhancement in the measurement of 5 endogenous steroids by LC-MS/MS combined with differential ion mobility spectrometry.

Ray JA, Kushnir MM, Yost RA, Rockwood AL, Wayne Meikle A.

Clin Chim Acta. 2015 Jan 1;438:330-6. doi: 10.1016/j.cca.2014.07.036. Epub 2014 Aug 9.

PMID:
25110813
5.

Reversed-phase high-performance liquid chromatography separation of adrenal steroids prior to radioimmunoassay: application in congenital adrenal hyperplasia.

Fernandes VT, Ribeiro-Neto LM, Lima SB, Vieira JG, Verreschi IT, Kater CE.

J Chromatogr Sci. 2003 May-Jun;41(5):251-4.

PMID:
12841953
6.
7.

Analysis of 17 α-hydroxyprogesterone in bloodspots by liquid chromatography tandem mass spectrometry.

Salter SJ, Cook P, Davies JH, Armston AE.

Ann Clin Biochem. 2015 Jan;52(Pt 1):126-34. doi: 10.1177/0004563214530676. Epub 2014 May 19.

PMID:
24842631
8.

Rapid diagnosis of congenital adrenal hyperplasia by high performance liquid chromatography.

Weisman Y, Bar A, Root A, Spirer Z, Golander A.

Clin Chim Acta. 1984 Mar 27;138(1):1-8.

PMID:
6609026
10.

Radioimmunoassay for 21-deoxycortisol: clinical applications.

Gueux B, Fiet J, Pham-Huu-Trung MT, Villette JM, Gourmelen M, Galons H, Brerault JL, Vexiau P, Julien R.

Acta Endocrinol (Copenh). 1985 Apr;108(4):537-44.

PMID:
2986404
11.

Evaluation of 21-deoxycortisol as a marker for the detection of heterozygous carriers of 21-hydroxylase deficiency.

Milewicz A, Afelska A, Wasikowa R, Romer T.

Endokrynol Pol. 1993;44(2):187-93.

PMID:
8055790
12.
13.

The application of a new highly-sensitive radioimmunoassay for plasma 21-deoxycortisol to the detection of steroid-21-hydroxylase deficiency.

Fiet J, Villette JM, Galons H, Boudou P, Burthier JM, Hardy N, Soliman H, Julien R, Vexiau P, Gourmelen M, et al.

Ann Clin Biochem. 1994 Jan;31 ( Pt 1):56-64.

PMID:
8154853
14.
15.

Measurement of steroids in rats after exposure to an endocrine disruptor: mass spectrometry and radioimmunoassay demonstrate similar results.

Riffle BW, Henderson WM, Laws SC.

J Pharmacol Toxicol Methods. 2013 Nov-Dec;68(3):314-22. doi: 10.1016/j.vascn.2013.07.003. Epub 2013 Jul 18.

PMID:
23871967
16.

Clinical determination of 17-hydroxyprogesterone in serum by LC-MS/MS: comparison to Coat-A-Count RIA method.

Etter ML, Eichhorst J, Lehotay DC.

J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Aug 7;840(1):69-74. Epub 2006 Jun 5.

PMID:
16737854
17.

Functional glucocorticoid receptor gene variants do not underlie the high variability of 17-hydroxyprogesterone screening values in healthy newborns.

Schreiner F, Tozakidou M, Maslak R, Holtkamp U, Peter M, Gohlke B, Woelfle J.

Eur J Endocrinol. 2009 Apr;160(4):667-73. doi: 10.1530/EJE-08-0639. Epub 2009 Jan 27.

19.

[Mass spectrometry for steroid assays].

Dufour-Rainfray D, Moal V, Cloix L, Mathieu E, Gauchez AS, Brossaud J, Corcuff JB, Fraissinet F, Collet C, Boux de Casson F, Guilloteau D, Emond P, Reynier P.

Ann Biol Clin (Paris). 2015 Jan-Feb;73(1):70-8. doi: 10.1684/abc.2014.0988. Review. French.

20.

LC-MS/MS based determination of basal- and ACTH-stimulated plasma concentrations of 11 steroid hormones: implications for detecting heterozygote CYP21A2 mutation carriers.

Kulle AE, Riepe FG, Hedderich J, Sippell WG, Schmitz J, Niermeyer L, Holterhus PM.

Eur J Endocrinol. 2015 Oct;173(4):517-24. doi: 10.1530/EJE-14-1084.

Supplemental Content

Support Center